Financial Performance Overview
Borosil Scientific Limited reported strong financial results for FY 2025-26 with standalone revenue growth of 8.93% to ₹427.53 crores and profit after tax increasing 13.45% to ₹39.72 crores. Consolidated performance showed revenue of ₹467.34 crores (up 6.58%) and PAT of ₹34.58 crores (up 29.41%). The company maintained a robust financial position with net cash of ₹134.99 crores, zero debt-to-equity ratio, and improved return on capital employed at 13.28%.
Operational Excellence and Strategic Initiatives
The company operates through four business divisions: Laboratory Consumables, Laboratory Instrumentation, Pharmaceutical Primary Packaging, and Process Systems. Key operational achievements include receiving the TPM Significant Award for the Bharuch plant, expansion into water purification systems through German technical collaboration, and investment in fully automated vial manufacturing lines at the Nashik plant. The product portfolio expanded to over 4,500 SKUs with 95% success rate in delivering products within 24 hours and presence in over 90 countries.
Corporate Governance and Management Changes
The Board has recommended the reappointment of Mr. Vinayak Madhukar Patankar as Whole-time Director & CEO for another term, citing his extensive experience and contributions to company growth. His FY 2024-25 remuneration was ₹21.182 million, deemed in line with industry standards. Mr. Pradeep Kumar Kheruka retires by rotation and is offered for reappointment. The company saw changes in key managerial personnel with Mr. Ramavtar Sharma appointed as Company Secretary & Compliance Officer following Mr. Sanjay Gupta's resignation.
Related Party Transactions and Capital Structure
Significant related party transactions with Borosil Limited include sales up to ₹200 crores and functional support services up to ₹30 crores. The company invested in its subsidiary Goel Scientific Glass Works Limited by converting inter-corporate deposits into equity, increasing ownership to 99.37%. Share capital increased marginally to ₹8.89 crores through allotment of 13,747 equity shares upon exercise of stock options under SP-ESOP 2023.
Annual General Meeting and Shareholder Approvals
The 35th AGM is scheduled for September 25, 2026, to be held virtually via video conference. Shareholders will vote on key resolutions including adoption of financial statements, reappointment of directors, approval of material related party transactions, raising funds up to ₹250 crores, and amendments to employee stock option schemes. The remote e-voting period commences on September 22, 2026.
Risk Management and Market Opportunities
The company maintains exposure to foreign exchange risk with unhedged positions in USD and EUR, and credit risk with trade receivables of ₹785.11 million. Market opportunities include benefiting from 'China Plus One' supply chain shifts, import substitution driven by 'Make in India' initiatives, and surging biologics and R&D capex in the pharmaceutical sector. The company is well-positioned to capitalize on increasing global pharma investments in India.
ESG and Sustainability Commitments
Environmental initiatives resulted in carbon emission reduction of 871.02 tCO₂, renewable energy generation of 1,076 kW from solar power, and water recycling of 6,039 kL. CSR expenditure of ₹65.59 lakhs exceeded requirements, focusing on education, healthcare, and animal welfare. Employee welfare programs covered 616 permanent employees and 1,006 contract workers with extensive training programs and zero fatal incidents.